IQV stock forecast: what analysts expect
Wall Street analysts covering IQVIA Holdings Inc. currently rate the stock a Strong Buy on average, with a mean 12-month price target of $275.17 — +13.8% versus the last price of $241.71. Targets reflect analyst opinion, not a guarantee.
IQV historical returns
Based on monthly dividend-adjusted prices. See the full breakdown on what if you had invested in IQV.
IQV annual returns by year
Congress trading in IQV
4 members of Congress have disclosed trading IQV — 6 purchases and 3 sales worth an estimated $288,000. Most recent disclosure: May 15, 2025.
Insider activity in IQV
IQV's own executives and directors have made 0 open-market purchases ($0) and 8 sales ($29.2M) in the last 90 days, per SEC Form 4 filings. Most recent: Aug 3, 2026.
| Aug 3, 2026 | Staub W Richard | See Remarks | Sell | $1.3M |
| Jul 31, 2026 | Patel Bhavik | See Remarks | Sell | $436,426 |
| Jul 29, 2026 | Sherbet Eric | See Remarks | Sell | $1.2M |
| Jul 29, 2026 | Cherofsky Keriann | See Remarks | Sell | $136,827 |
| Jul 29, 2026 | Bousbib Ari | See Remarks | Sell | $1.1M |
About IQVIA Holdings Inc.
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.
IQV Key Statistics
IQV in plain English
- P/E ratio (30.0) — how many dollars you pay for each $1 of IQV's yearly profit. That's a fairly normal range.
- ROE (22.82%) — how efficiently the company turns shareholders' money into profit. Above ~20% is considered strong.
- Profit margin (8.10%) — of every $1 in sales, this is what's left as profit after all costs.
- Dividend — IQV doesn't pay a meaningful dividend; the return here comes from the share price, not cash payouts.
IQV stock: frequently asked questions
What is IQVIA Holdings Inc.'s stock price today?
IQVIA Holdings Inc. (IQV) last traded at $241.71 on the NYSE. Over the past 52 weeks the stock has traded between $154.50 and $251.36.
Is IQV stock a buy or a sell?
Wall Street analysts' consensus rating on IQV is "Strong Buy", with an average 12-month price target of $275.17 — about +13.8% versus the current price of $241.71. Analyst targets are opinions, not guarantees; always do your own research.
How much would $1,000 invested in IQV 10 years ago be worth today?
A $1,000 investment in IQVIA Holdings Inc. made 10 years ago would be worth about $3,127 today (dividends reinvested) — a total return of 213%, or 12.1% per year.
Does IQV pay a dividend?
No — IQVIA Holdings Inc. does not currently pay a meaningful dividend. Returns for shareholders come from changes in the share price.
What is IQV's P/E ratio?
IQV trades at a trailing price-to-earnings ratio of 30.0, and 16.7 times expected forward earnings. The P/E ratio tells you how many dollars investors pay for each $1 of the company's annual profit.
Do members of Congress trade IQV stock?
Yes — 4 members of Congress have disclosed trades in IQV under the STOCK Act, totaling 6 purchases and 3 sales worth an estimated $288,000.
What is IQVIA Holdings Inc.'s ticker symbol?
IQVIA Holdings Inc. trades under the ticker symbol IQV on the NYSE.
Compare IQV with peers
Data last refreshed from public sources. Figures may be delayed. Not investment advice.